Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 1616 • ACR Convergence 2020
Systematic Review of Effectiveness Outcomes Reported in Rheumatology Transition Literature
Heather Bannerman¹, Karen Beattie¹, Avanti Patel², Milica Tanic², Michelle Batthish³ and Mark Matsos², ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: In young patients with rheumatologic disease, transition from pediatric to adult care is a complex process. Poor transitional care leads to health deterioration, loss…
Abstract Number: 0711 • ACR Convergence 2020
Alternative Dosing of Biologic Therapies Is Frequent Among Children with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Colleen Correll¹, Peter Shrader², Anne Dennos³, Thomas Phillips², Natalie Shiff⁴, Ruud Verstegen⁵ and Timothy Beukelman⁶, ¹University of Minnesota, Minneapolis, MN, ²Duke University, Durham, ³Duke University, Durham, NC, ⁴Florida, Gainesville, FL, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic agents are integral to the treatment of juvenile idiopathic arthritis (JIA) and associated uveitis. Pediatric rheumatologists may increase the dosage of biologics beyond…
Abstract Number: 0730 • ACR Convergence 2020
To Taper or Not to Taper in Juvenile Idiopathic Arthritis: Is There a Risk of Development of Uveitis Flares?
Maria Teran¹, Alina Lucica Boteanu², Carlos Guillen¹, Cristina Pijoan¹, Jose Quinones¹, Veronica Garcia³, Ivan Del Bosque-Granero³, Laura Calvo-Sanz⁴ and Mónica Vázquez⁴, ¹Hospital Ramon y Cajal, Madrid, Madrid, Spain, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain
Background/Purpose: To determine the association between the occurrence of uveitis flares in patients with Juvenile Idiopathic Arthritis (JIA) and the de-intensification of immunosuppressive treatment.Methods: We…
Abstract Number: 1617 • ACR Convergence 2020
New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Esi Morgan², Sheetal Vora³, Mileka Gilbert⁴, Cagri Yildirim-Toruner⁵, Nancy Griffin⁶, Kerry Ferraro⁷, Stephanie Loos⁶, Tingting Qiu⁸, Anne Paul⁹, Jon Burnham¹⁰, Michelle Batthish¹¹, Beth Gottlieb¹², Danielle Bullock¹³, Melissa Hazen¹⁴, Ronald Laxer¹⁵, Tzielan Lee¹⁶, Melissa Mannion¹⁷, Judyann Olson¹⁸, Nancy Pan¹⁹, Michael Shishov²⁰, Charles Spencer²¹, Jennifer E Weiss²² and C. April Bingham²³, ¹Children's Mercy Kansas City, Overland Park, KS, ²Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Medical University of South Carolina, Charleston, SC, ⁵Nationwide Children's Hospital, Houston, TX, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, ⁷Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, ¹⁰Children's Hospital of Philadelphia, Philadelphia, PA, ¹¹McMaster Children's Hospital, Hamilton, ON, Canada, ¹²Cohen Children's Medical Center, Lake Success, NY, ¹³University of Minnesota, Minneapolis, MN, ¹⁴Boston Children's Hospital, Boston, MA, ¹⁵The Hospital for Sick Children, Toronto, ON, Canada, ¹⁶Stanford University School of Medicine, Palo Alto, CA, ¹⁷University of Alabama at Birmingham, Birmingham, AL, ¹⁸Medical College of Wisconsin, Milwaukee, WI, ¹⁹Hospital for Special Surgery, New York, NY, ²⁰Phoenix Children's Hospital, Phoenix, AZ, ²¹University of Mississippi, Jackson, MS, ²²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²³Penn State Children's Hospital, Allentown, PA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning network to support pediatric rheumatology centers in improving care delivery and patient…
Abstract Number: 0712 • ACR Convergence 2020
Switching from Reference to Biosimilars Does Not Reduce Efficacy and Safety in Juvenile Idiopathic Arthritis
Ilaria Maccora¹, Gabriele Simonini², Alessandra Bettiol³, Ilaria Pagnini⁴, Niccolò Lombardi⁵, Valerio Maniscalco⁶, Giada Crescioli⁵, Edoardo Marrani⁷, Roberto Bonaiuti⁵, Maria Vincenza Mastrolia⁸, Claudia Ravaldi⁹ and Alfredo Vannacci⁵, ¹Paediatric Rheumatology Unit, Anna Meyer Children's University Hospital, School of Human Health Science, Florence, Italy, Florence, Italy, ²Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy, ³2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy, Florence, ⁴1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy, florence, Italy, ⁵2. Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, Florence, Italy., Florence, Italy, ⁶1. Rheumatology Unit, Anna Meyer Children’s Hospital and Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Paediatric, University of Florence, Florence, Italy., florence, Italy, ⁷University of Florence, Firenze, Italy, ⁸Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy, Florence, Toscana, Italy, ⁹3. Department of Health Sciences, University of Florence, Florence, Italy., Florence, Italy
Background/Purpose: Limited data about the use of biosimilar are available in children with Juvenile Idiopathic Arthritis (JIA). To evaluate the long-term efficacy and safety of switching…
Abstract Number: 0731 • ACR Convergence 2020
Comparing S100 Proteins and Cytokine Levels in Tears Based on Uveitis Activity Laterality in Children with JIA-associated Uveitis and Non-JIA-U
Jackeline Rodriguez-Smith¹, Virginia Miraldi Utz², Amy Cassedy¹, Sherry Thornton¹, Grant Schulert³, Alyssa Sproles⁴, Najima Mwase¹, Theresa Hennard¹, Mekibib Altaye², Alexei Grom¹ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati
Background/Purpose: The pathogenesis of pediatric uveitis remains unclear. Studies of biomarkers using aqueous humor (AqH) identified S100 proteins, cytokines, and chemokines as potential biomarkers of…
Abstract Number: 1634 • ACR Convergence 2020
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?
Therese Posas-Mendoza¹, Cara McLeod¹, William Davis² and Robert Quinet², ¹Ochsner Medical Center, New Orleans, LA, ²Dept of Rheumatology, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease characterized by immune-overstimulation and a hyperinflammatory response resulting in cytokine storm and multi-organ failure.1 Secondary HLH…
Abstract Number: 0713 • ACR Convergence 2020
Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry
Daniel J Lovell¹, Hermine Brunner², Nikolay Tzaribachev³, Esi Morgan², Gabriele Simonini⁴, Thomas Griffin⁵, Ekaterina Alexeeva⁶, John Bohnsack⁷, Andrew Zeft⁸, Gerd Horneff⁹, Richard Vehe¹⁰, Valda Stanevicha¹¹, Stacey Tarvin¹², Maria Trachana¹³, Adam Huber¹⁴, Ilonka Orban¹⁵, Jason Dare¹⁶, Ivan Foeldvari¹⁷, Pierre Quartier¹⁸, Alyssa Dominique¹⁹, Tzuyung Douglas Kou¹⁹, Robert Wong¹⁹, Alberto Martini²⁰ and Nicolino Ruperto²⁰, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ⁴Anna Meyer Children's Hospital, Firenze, Italy, ⁵Levine Children's Hospital, Charlotte, NC, ⁶Scientific Center of Children’s Health of RAMS, Moscow, Russia, ⁷University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁸Cleveland Clinic, Cleveland, OH, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰University of Minnesota, Minneapolis, MN, ¹¹Riga Stradins University, Riga, Latvia, ¹²Riley Children’s Health, Indianapolis, IN, ¹³Aristotle University of Thessaloniki, Thessaloníki, Greece, ¹⁴Dalhousie University, Halifax, NS, Canada, ¹⁵National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ¹⁶University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁷Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁸Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ¹⁹Bristol-Myers Squibb Company, Princeton, NJ, ²⁰PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients with JIA has been demonstrated…
Abstract Number: 0733 • ACR Convergence 2020
Practice Patterns for Tapering Medications in the Treatment of JIA-associated Uveitis
Ivan Foeldvari¹, Jens Klotsche², Sheila Angeles-Han³, Jordi Anton⁴, Gabriele Simonini⁵, Nadine Groesch² and Jean Baer⁶, ¹Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ²German Rheumatism Research Center, Berlin, Germany, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Sant Joan de Déu Hospital, Madrid, Spain, ⁵Anna Meyer Children's Hospital, Firenze, Italy, ⁶Hamburg Centre for Pediatric and Adolescence Rheumatology, Hamburg, Germany
Background/Purpose: Juvenile idiopathic arthritis associated uveitis (JIAU) is the most common extra-articular manifestation of JIA, and occurs in approximately 10% of affected children. Although there…
Abstract Number: 1682 • ACR Convergence 2020
Goal-Setting Improves Transition Readiness in Adolescents with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Teresa Semalulu¹, Karen Beattie¹, Jeanine McColl¹, Arzoo Alam², Steffy Thomas², Julie Herrington³, Jan Willem Gorter², Tania Cellucci², Stephanie Garner¹, Liane Heale², Mark Matsos¹ and Michelle Batthish⁴, ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³ACPAC - University of Toronto, Hamilton, ON, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: The transition from pediatric to adult rheumatology care is associated with increased morbidity, mortality and loss to follow-up. This is largely due to a…
Abstract Number: 0714 • ACR Convergence 2020
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry
Daniel J Lovell¹, Nikolay Tzaribachev², Esi Morgan³, Gabriele Simonini⁴, Thomas Griffin⁵, Ekaterina Alexeeva⁶, John Bohnsack⁷, Andrew Zeft⁸, Gerd Horneff⁹, Richard Vehe¹⁰, Valda Stanevicha¹¹, Stacey Tarvin¹², Maria Trachana¹³, Adam Huber¹⁴, Daniel Kietz¹⁵, Ilonka Orban¹⁶, Jason Dare¹⁷, Ivan Foeldvari¹⁸, Pierre Quartier¹⁹, Alyssa Dominique²⁰, Tzuyung Douglas Kou²⁰, Robert Wong²⁰, Alberto Martini²¹, Hermine Brunner³ and Nicolino Ruperto²², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Anna Meyer Children's Hospital, Firenze, Italy, ⁵Levine Children's Hospital, Charlotte, NC, ⁶Scientific Center of Children’s Health of RAMS, Moscow, Russia, ⁷University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁸Cleveland Clinic, Cleveland, OH, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰University of Minnesota, Minneapolis, MN, ¹¹Riga Stradins University, Riga, Latvia, ¹²Riley Children’s Health, Indianapolis, IN, ¹³Aristotle University of Thessaloniki, Thessaloníki, Greece, ¹⁴Dalhousie University, Halifax, NS, Canada, ¹⁵Children’s Hospital of Pittsburgh, Pittsburgh, PA, ¹⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ¹⁷University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁸Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁹Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ²⁰Bristol-Myers Squibb Company, Princeton, NJ, ²¹PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²²Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…
Abstract Number: 0734 • ACR Convergence 2020
Differences and Similarities Between down Syndrome-associated Arthritis and Juvenile Idiopathic Arthritis in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Jordan Jones¹, Chelsey Smith², Daniel J Lovell³ and Mara Becker⁴, ¹Children's Mercy Kansas City, Kansas City, MO, ²Children's Mercy Kansas City, Holden, MO, ³PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Duke University School of Medicine, Durham, NC
Background/Purpose: Down syndrome-associated arthritis (DA) is under-recognized with delay in diagnosis (1). The majority of those with DA present with polyarticular, rheumatoid factor (RF) and…
Abstract Number: 1683 • ACR Convergence 2020
Ready or Not? Measuring Readiness for Transition to Adult Care in Adolescents with JIA & jSLE
Jeanine McColl¹, Teresa Semalulu¹, Arzoo Alam², Steffy Thomas², Julie Herrington³, Jan Willem Gorter², Tania Cellucci², Stephanie Garner², Liane Heale², Mark Matsos², Karen Beattie¹ and Michelle Batthish⁴, ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³The Canadian Arthritis Society, Hamilton, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: Transitioning from pediatric to adult care represents a particularly vulnerable period among patients with JIA and jSLE. The shift to adult care is often…
Abstract Number: 0715 • ACR Convergence 2020
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept
Nicolino Ruperto¹, Hermine I Brunner², Alberto Berman³, Francisco Ávila-Zapata⁴, Gerd Horneff⁵, Maria Alessio⁶, Mara Becker⁷, Alexandre Belot⁸, Ruben Burgos-Vargas⁹, Alina Boteanu¹⁰, Claudia Goldenstein-Schainberg¹¹, Iloite Scheibel¹², Maria Teresa Terreri¹³, Lawrence Zemel¹⁴, Robert Wong¹⁵, Margarita Askelson¹⁵, Marleen Nys¹⁶, Alberto Martini¹⁷ and Daniel J Lovell², ¹Istituto Giannina Gaslini, Genova, Italy, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Universidad Nacional de Tucumán and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁴Star Medica Hospital, Merida, Yucatan, Mexico, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Università di Napoli Federico II, Naples, Italy, ⁷Duke University School of Medicine, Durham, NC, ⁸Centre Hospitalier Universitaire de Lyon, Lyon, France, ⁹Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, ¹⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹¹University of São Paulo, São Paulo, Brazil, ¹²Hospital Criança Conceição, Porto Alegre, Brazil, ¹³Federal University of São Paulo, São Paulo, Brazil, ¹⁴Connecticut Children’s Medical Center, Hartford, CT, ¹⁵Bristol-Myers Squibb Company, Princeton, NJ, ¹⁶Bristol-Myers Squibb Company, Braine-L’Alleud, Belgium, ¹⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Effectiveness of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label Phase III international study (NCT01844518). Here we assess…
Abstract Number: 1148 • ACR Convergence 2020
The SHARE Recommendations on Diagnosis and Treatment of Systemic JIA
Arjen Leek¹, Jordi Anton², Tadej Avcin³, Fabrizio De Benedetti⁴, Victor Boom¹, Claudia Bracaglia⁵, Paul Brogan⁶, Tamas Constantin⁷, Alessandro Consolaro⁸, Pavla Dolezalova⁹, Despina Eleftheriou¹⁰, Helen Foster¹¹, Claas Hinze¹², Isabelle Koné-Paut¹³, Kirsten Minden¹⁴, Francesca Minoia¹⁵, Pierre Quartier¹⁶, Angelo Ravelli⁸, Nicolino Ruperto¹⁷, Joost Swart¹⁸, Yosef Uziel¹⁹, Helmut Wittkowski²⁰, Carine Wouters²¹, Mojca Zajc Avramovitz²², Nico Wulffraat¹⁸ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Sant Joan de Déu Hospital, Madrid, Spain, ³Ljubljana University Medical Centre, Ljubljana, Slovenia, ⁴Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁵Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁶UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁷Semmelweiss University Hospital, Budapest, Hungary, ⁸Università degli Studi di Genova, Genoa, Italy, ⁹University Hospital Prague, Prague, Czech Republic, ¹⁰UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, ¹¹Newcastle University, Newcastle upon Tyne, United Kingdom, ¹²University Hospital M�nster, M�nster, Germany, ¹³Necker Hospital, Paris, France, ¹⁴Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ¹⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ¹⁶Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ¹⁷Istituto Giannina Gaslini, Genova, Italy, ¹⁸IRCCS Istituto Giannina Gaslini, PRINTO, Genoa, Italy, Genova, Italy, ¹⁹Meir Medical Center, Kfar Saba, Israel, ²⁰University Hospital Muenster, Muenster, Germany, ²¹University Hospital Leuven, Leuven, Belgium, ²²University Hospital Ljubljana, Ljubljana, Slovenia
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare, complex auto-inflammatory disease with significant morbidity including fever, rash, serositis and articular problems. With the availability…